PE/VC  Invus

https://www.invus.com/





     Office Locations:

750 Lexington Avenue, 30th Floor
New York, NY 10022
Phone: 212-371-1717
Fax: 212-371-1829

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early
  • Middle Market


 

Industries:

  • Business Services
  • Consumer Products & Services
  • Education & Training
  • Medical Device
  • Software & Internet

  •  

    Description:

    Founded 1985, Invus is a New York-based investment firm with additional offices in Hong Kong and Paris. Invus invests in a variety of equity transactions, including buyouts, longer term public equity investments, venture capital, and expansion financings. Invus manages in excess of $10 billion of capital. Invus has achieved both cash on cash multiples and annual internal rates of return that are at the very top of the private equity industry. Invus manages interests in a broad range of industries, including consumer goods, consumer services, education, software, biotechnology and medical devices. Since 1998, Invus has been the largest investor in QuestMark Partners, a late-stage venture capital firm based in Baltimore, Maryland. Initial investments in companies have been as low as $10 million, and as high as $800 million.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Aflalo Guimaraes Managing Director
    Benjamin Felt Managing Director
    Christopher Sobecki Managing Director
    Clare Joyce Director
    Evren Bilimer Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/02/2024


      Triveni Bio


      MA


      $115,000,000


      Series B


      08/04/2024


      Scorpion Therapeutics


      MA


      $150,000,000


      Series C


      06/25/2024


      Exsilio Therapeutics


      NY


      $82,000,000


      Series A


      04/25/2024


      Endeavor BioMedicines


      CA


      $132,500,000


      Series C


     

    Portfolio companies include:

     

    Recent News: